Table 4.
Multivariate analysis of transplants outcomes
| Variable | aGvHD II–IV | cGvHD | NRM | RI | LFS | OS | GRFS | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | |
| Donor type | ||||||||||||||
| MSD | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||||
| MUD | 1.25 (0.73–2.13) | 0.42 | 1.84 (1.02–3.34) | 0.04 | 1.06 (0.47–2.38) | 0.89 | 0.78 (0.38–1.57) | 0.48 | 0.91 (0.54–1.55) | 0.74 | 1.05 (0.57–1.94) | 0,.7 | 1.02 (0.65–1.59) | 0,.3 |
| Haplo | 0.99 (0.62–1.57) | 0.96 | 1.03 (0.59–1.79) | 0.93 | 1.16 (0.6–2.25) | 0.66 | 0.74 (0.43–1.28) | 0.28 | 0.91 (0.59–1.39) | 0.65 | 1.13 (0.68–1.86) | 0.64 | 0.96 (0.66–1.4) | 0.84 |
| Patient’s age per 10 years1 | 1.01 (0.9–1.14) | 0,83 | 1.03 (0.89–1.18) | 0,72 | 1.3 (1.1–1.55) | 0,002 | 0.95(0.81–1.11) | 0,5 | 1.09 (0.97–1.22) | 0,14 | 1.15 (1.02–1.31) | 0,03 | 1.07 (0.97–1.18) | 0,17 |
| Patient’s gender | ||||||||||||||
| Male | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||||
| Female | 0.84 (0.59–1.19) | 0.33 | 0.59 (0.4–0.87) | 0.008 | 0.67 (0.41–1.09) | 0.1 | 0.79 (0.5–1.24) | 0.31 | 0.74 (0.53–1.03) | 0.08 | 0.68 (0.47–1) | 0.04 | 0.75 (0.56–0.99) | 0.04 |
| Karnofsky performance status | ||||||||||||||
| Poor (< 90) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||||
| Good (≥ 90) | 1.12 (0.73–1.7) | 0.61 | 0.65 (0.39–1.06) | 0.09 | 0.78 (0.45–1.36) | 0.55 | 1.2 (0.68–2.13) | 0.53 | 0.94 (0.63–1.39) | 0.75 | 0.82 (0.53–1.27) | 0.38 | 1.03 (0.73–1.47)) | 0.86 |
| Patient’s CMV serostatus | ||||||||||||||
| Negative | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||||
| Positive | 0.98 (0.66–1.44) | 0.90 | 0.76 (0.5–1.17) | 0.21 | 1.45 (0.78–2.71) | 0.24 | 1.46 (0.85–2.52) | 0.17 | 1.44 (0.95–2.17) | 0.08 | 1.21 (0.77–1.91) | 0.4 | 1.05 (0.75–1.46) | 0.78 |
| Cytogenetics | ||||||||||||||
| Philadephia neg | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||||
| Philadephia pos | 1.02 (0.7–1.47) | 0.94 | 0.8 (0.53–1.21) | 0.3 | 0.87 (0.52–1.43) | 0.58 | 0.54 (0.32–0.9) | 0.02 | 0.71 (0.5–1.02) | 0.06 | 0.67 (0.45–1) | 0.05 | 0.8 (0.59–1.09) | 0.16 |
| Philadephia unknown | 0.75 (0.43–1.31)) | 0.32 | 1.06 (0.57–1.94) | 0.86 | 1.07 (0.5–2.29)) | 0.87 | 0.80 (0.43–1.49) | 0.48 | 0.89 (0.54–1.46) | 0.64 | 0.86 (0.49–1.52) | 0.61 | 0,78 (0.5–1.22) | 0.27 |
| Type of conditioning | ||||||||||||||
| Based on chemotherapy | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||||
| Based on TBI | 1.17 (0.85–1.63) | 0.34 | 0.79 (0.52–1.2) | 0,.7 | 0.68 (0.41–1.13) | 0.13 | 0.68 (0.45–1.05) | 0.08 | 0.70 (0.51–0.98) | 0.04 | 0.78 (0.53–1.14) | 0.20 | 0.78 (0.58–1.03) | 0.08 |
| Year of transplant1 | 0.98 (0.91–1.07) | 0.69 | 0.90 (0.81–0.99) | 0.03 | 0.93 (0.83–1.04) | 0.21 | 0.95 (0.85–1.05) | 0.28 | 0.93 (0.86–1) | 0.07 | 0.90 (0.82–0.98) | 0.01 | 0.97 (0.91–1.04) | 0,47 |
Bold statistically significant variables for specific outcomes
1. Continuous variable
GvHD, graft-versus-host disease; CI, confidence interval; NRM, non-relapse mortality; RI, relapse incidence; LFS, leukemia-free survival; OS, overall survival; GRFS, graft-versus-host disease and relapse-free survival; TBI, total body irradiation